{
  "response": {
    "text": "Based on the clinical trial NCT02294461 and the provided search results:\n\n*   Among more effective regime ingredients, **Enzalutamide** is the ingredient that starts with the letter \"E\".\n\n*   Regarding the exclusivity date for Enzalutamide, the search results do not provide a specific exclusivity date for Enzalutamide that would have been in effect up to December 2024. However, Lupin received FDA approval for generic Emtricitabine and Tenofovir Alafenamide tablets on December 13, 2024, and secured 180 days of market exclusivity.\n",
    "citations": []
  }
}